Synektik to produce and distribute Axumin prostate cancer PET agent in Poland

…an increase of 30% year on year. Both FDG and special radiotracers contributed to the increase. Synektik is in the middle of a Phase II study of an innovative radiotracer for myocardial perfusion imaging, which it claims can revolutionise cardiological diagnostics worldwide.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.